Impax Laboratories, Inc. (NASDAQ:IPXL) received a $21.00 price target from analysts at Deutsche Bank AG in a note issued to investors on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s target price would indicate a potential upside of 16.02% from the company’s previous close.

IPXL has been the topic of a number of other research reports. Vetr lowered Impax Laboratories from a “strong-buy” rating to a “strong sell” rating and set a $10.55 target price on the stock. in a report on Monday, April 24th. Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a report on Monday, May 8th. BMO Capital Markets reissued a “hold” rating and set a $16.00 price objective on shares of Impax Laboratories in a report on Friday, June 23rd. Royal Bank Of Canada reissued a “sector perform” rating and set a $10.00 price objective on shares of Impax Laboratories in a report on Sunday, April 2nd. Finally, Guggenheim reissued a “buy” rating and set a $20.00 price objective on shares of Impax Laboratories in a report on Monday, March 27th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $18.03.

Impax Laboratories (IPXL) traded up 8.06% during trading on Monday, hitting $18.10. The stock had a trading volume of 3,419,069 shares. Impax Laboratories has a 52 week low of $7.75 and a 52 week high of $31.85. The company’s 50-day moving average is $15.78 and its 200 day moving average is $13.40. The firm’s market cap is $1.30 billion.

Impax Laboratories (NASDAQ:IPXL) last released its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.12 by $0.01. The business had revenue of $184.40 million during the quarter, compared to analyst estimates of $193.17 million. Impax Laboratories had a negative net margin of 71.50% and a positive return on equity of 7.71%. The business’s quarterly revenue was down 18.2% compared to the same quarter last year. During the same period last year, the business earned $0.43 EPS. Equities analysts expect that Impax Laboratories will post $0.65 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Impax Laboratories, Inc. (IPXL) Given a $21.00 Price Target at Deutsche Bank AG” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/07/17/impax-laboratories-inc-nasdaqipxl-price-target-raised-to-21-00.html.

Several institutional investors have recently bought and sold shares of the company. State of Alaska Department of Revenue increased its position in Impax Laboratories by 78.7% in the second quarter. State of Alaska Department of Revenue now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $234,000 after buying an additional 6,408 shares during the period. Bank of Montreal Can increased its position in Impax Laboratories by 0.9% in the second quarter. Bank of Montreal Can now owns 54,383 shares of the specialty pharmaceutical company’s stock valued at $875,000 after buying an additional 509 shares during the period. Appleton Partners Inc. MA bought a new position in Impax Laboratories during the second quarter valued at approximately $191,000. Fox Run Management L.L.C. bought a new position in Impax Laboratories during the second quarter valued at approximately $541,000. Finally, Point72 Asset Management L.P. increased its position in Impax Laboratories by 88.4% in the first quarter. Point72 Asset Management L.P. now owns 1,095,600 shares of the specialty pharmaceutical company’s stock valued at $13,859,000 after buying an additional 514,200 shares during the period. Institutional investors and hedge funds own 83.87% of the company’s stock.

Impax Laboratories Company Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Analyst Recommendations for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.